AstraZeneca PLC (AZN) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Cambridge, United Kingdom. Le PDG actuel est Pascal Claude Roland Soriot.
AZN a date d'introduction en bourse 1993-05-12, 94,300 employés à temps plein, cotée sur le NYSE, une capitalisation boursière de $316.85B.
AstraZeneca PLC is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. The company maintains a diverse portfolio of marketed products across multiple therapeutic areas, including cardiovascular, renal, metabolic, and oncology treatments such as Tagrisso, Imfinzi, and Lynparza, alongside vaccines and rare disease medications including Vaxzevria and Soliris. AstraZeneca operates through a network of distributors and representative offices across the United Kingdom, Europe, the Americas, Asia, Africa, and Australasia, serving both primary and specialty care physicians. The company actively pursues innovation partnerships with organizations including Neurimmune AG, BenevolentAI, and Absci Corporation to advance drug discovery and development in areas such as neurodegenerative diseases, systemic lupus erythematosus, and oncology. Headquartered in Cambridge, United Kingdom, AstraZeneca was incorporated in 1992 and adopted its current name in 1999.
